Interferon in combination with vinblastine in advanced malignant melanoma. A phase I–II study

Publisher Website
Google Scholar
Abstract
Nineteen patients with advanced malignant melanoma were treated with a combination of recombinant alfa-interferon (α-IFN) and vinblastine (VBL). The α-IFN was administered subcutaneously daily at an initial dose of 3 × 106 IU escalating to a maximal dose of 9 × 106 U daily for the first 10 weeks followed by 3 ×/week for 6 months. The VBL was given once every week at a dose of 0.025 mg/kg. Of the 19 patients 17 were evaluable for tumor response. Thirteen patients had received chemotherapy previously. Median performance status (World Health Organization) was 0, ranging from 0 to 2. One complete response and one partial response was observed. All patients experienced flu-like symptoms attributed to α-IFN. Leukopenia was observed in 12 patients and a planned dose escalation of VBL was undertaken for the patients only. It is concluded that combined α-IFN and VBL is only marginally effective in patients with advanced malignant melanoma who have had prior chemotherapy.